Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.

The analysis found that trial participants who received retatrutide (Eli Lilly) — an investigational triple agonist that activates the glucose-dependent insulinotropic polypeptide, glucagon-like ...

Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and delivering life-changing medicines to address some of the world's most pressin ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market ...

Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s disease, an inflammatory bowel disease that causes chronic abdominal pain.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Eli Lilly, the world’s largest drugmaker by market value, is in advanced talks to buy cancer-focused ...

For nearly a decade, Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. Now, with its business booming, the company is setting up a similar site 10 hours to the ...

Jan 13 (Reuters) - (This Jan. 13 story has been corrected to say 'drugmakers will ask,' not 'Eli Lilly has asked' to pause negotiations, after the company clarified, in the headline & paragraph 1 ...

Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound® (tirzepatide) provided a 47% greater relative weight ...

The first reveal of clinical data with Eli Lilly’s injectable ... the drug makes it through to market. Retatrutide targets GIP and GLP-1 – the same as Lilly’s fast-growing diabetes therapy ...

Earnings Report 5.305 USD Q4 2024 Earnings Release 02/06/2025 Earnings Report 4.954 USD Q1 2025 Earnings Release 05/01/2025 Earnings Report 5.770 USD Q2 2025 Earnings Release 08/07/2025 Earnings ...